Lantheus Holdings, Inc. (LNTH) Doses First Patient in SPARROW Phase 2/3 Registrational Trial

Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational trial of GRPR-targeted PET agent LNTH-2401 in prostate cancer, with Phase 3 planned to enroll ~400 participants and assess sensitivity and specificity vs histopathology.Material DetailsContext by AI AnalystThis is an early-to-m…